Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 31,605 shares at $50.11 ($1.6M) on 2013-04-05, disclosed to the SEC on 2013-04-09.
Scheduled sale ($1.6M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.11 | 9,910 | $497K | 31.6% |
| 2 | $49.49 | 21,695 | $1.1M | 68.4% |
| Total | $49.68 avg | 31,605 | $1.6M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |